NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/05/2023
Back to search
Official data from USPTO
TMALIN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
16
Latest update
09/05/2023
Trademark type
Word
Nice classes
5
Filing date
04/14/2022
Registration date
09/05/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/05/2023
Last transaction
09/05/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
06/09/2022
First use in commerce
06/09/2022
Drawing code
4
Owner type
99
Owner location
Suzhou, Jiangsu, CN
Examiner
JAGANNATHAN, SIDDHARTH
Law office
M50
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
MediLink Therapeutics(Suzhou)Co.,Ltd.
Representatives
Timothy T. Wang NI, WANG & MASSAND, PLLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Vaccines; Anti-cancer preparations; Biological preparations for the treatment of anemiacancercardiovascular system diseasescentral nervous system diseasesperipheral nervous system diseasescirculatory system diseasesdigestive system diseasesautoimmune diseasesbacteria-based diseases and infectious diseases; Chemical preparations for pharmaceutical or medical purposesfor treatment of anemiacancercardiovascular system diseasescentral nervous system diseasesperipheral nervous system diseasescirculatory system diseasesdigestive system diseasesautoimmune diseasesbacteria-based diseases and infectious diseases; Cytostatics for pharmaceutical purposes; Diagnostic kits consisting primarily of monoclonal antibodiesbuffersreagents for use in disease testing; Diagnostic preparations for medical purposes for detecting the presence of malignantinflammatory and autoimmune disorders and conditions and tissue trauma in humans; Diagnostic reagents for medicinal use; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of antibody-drug conjugate that facilitate the delivery of pharmaceutical preparations; Intravenous fluids used for rehydrationnutrition and the delivery of pharmaceutical preparations; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Medicinal preparations for anemiacancercardiovascular system diseasescentral nervous system diseasesperipheral nervous system diseasescirculatory system diseasesdigestive system diseasesautoimmune diseasesbacteria-based diseases and infectious diseases; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseasesbacteria-based diseases or disordersautoimmune diseases or disorderskidney diseases or disordersdiabetes; Pharmaceutical preparations for the prevention of anemiacancercardiovascular system diseasescentral nervous system diseasesperipheral nervous system diseasescirculatory system diseasesdigestive system diseasesautoimmune diseasesbacteria-based diseases and infectious diseases; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparationselixirs for the treatment of anemiacancercardiovascular system diseasescentral nervous system diseasesperipheral nervous system diseasescirculatory system diseasesdigestive system diseasesautoimmune diseasesbacteria-based diseases and infectious diseases; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseasesfor the treatment of cancer; Therapeutic pharmaceutical for the treatment of anemiacancercardiovascular system diseasescentral nervous system diseasesperipheral nervous system diseasescirculatory system diseasesdigestive system diseasesautoimmune diseasesbacteria-based diseases and infectious diseases; Tumor suppressing agents
Publications
History of USPTO decisions and trademark events.
16 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
09/05/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
08/04/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
08/03/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
08/03/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
08/03/2023
IUAF
USE AMENDMENT FILED
07/18/2023
EISU
TEAS STATEMENT OF USE RECEIVED
07/18/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
05/02/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/07/2023
PUBO
PUBLISHED FOR OPPOSITION
03/07/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/15/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/01/2023
DOCK
ASSIGNED TO EXAMINER
02/01/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/20/2022
NWAP
NEW APPLICATION ENTERED
04/18/2022
Continuous trademark protection
Get notified about every new filing that threatens TMALIN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.